Dr Reddy's Labs unveils Saxagliptin, Metformin Hydrochloride ER Tablets in US

Written by Ruchika Sharma Published On 11 Aug 2023 7:00 AM | Updated On 11 Aug 2023 7:00 AM

Dr Reddys Labs inks pact with Henlius for commercialization of multiple myeloma injection HLX15 in US, Europe

Hyderabad: Dr. Reddy's Laboratories Ltd. has announced its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market.

The product is a therapeutic equivalent generic version of KOMBIGLYZE XR (saxagliptin and metformin hydrochloride extended release) tablets, approved by U. S. Food and Drug Administration (USFDA).

Saxagliptin and metformin hydrochloride extended-release tablets are a combination of saxagliptin, a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.

According to WHO, Type 2 diabetes affects how your body uses sugar (glucose) for energy. It stops the body from using insulin properly, which can lead to high levels of blood sugar if not treated. Over time, type 2 diabetes can cause serious damage to the body, especially nerves and blood vessels. Factors that contribute to developing type 2 diabetes include being overweight, not getting enough exercise, and genetics.

Dr. Reddy’s Saxagliptin and Metformin Hydrochloride Extended-Release Tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30.

KOMBIGLYZE is a registered trademark of the AstraZeneca group of companies.

Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddys major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.

Read also: Dr Reddy's Labs proposed rituximab biosimilar application accepted for review by USFDA, EMA and MHRA

dr reddys labsdr reddys labs newsSaxagliptinMetformin Hydrochloride ER tabletskombiglyze ZR tabletsUSFDAAstraZeneca

Ruchika Sharma